April 4, 2024
University of Cincinnati Cancer Center researchers will present abstracts at the American Association for Cancer Research annual meeting 2024, April 5-10 in San Diego, California.
January 23, 2024
The Cancer Letter highlighted the University of Cincinnati Cancer Center’s Maria Czyzyk-Krzeska's new NIH-funded research that will investigate how copper contributes to the advancement and recurrence of clear cell renal cell carcinoma.
February 16, 2024
Medscape highlighted Project ECHO, a program piloted at the University of Cincinnati that trains primary care providers to manage epilepsy.
April 19, 2024
The University of Cincinnati's Leeya Pinder was featured in an Alabama.com/Reckon article about how self-testing for HPV could make preventative care more accessible to those facing the most barriers.
March 19, 2024
MSN and Neurology Live covered the results of a phase 3 trial co-led by a University of Cincinnati researcher that found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing symptoms for longer periods of time.
May 2, 2024
The University of Cincinnati's Vincent Martin was featured in a New York Magazine/The Cut article discussing the lack of solid evidence that chocolate is a migraine trigger.
May 8, 2024
The University of Cincinnati's Vince Martin spoke with South Bend television station WNDU on a recent study that found people who suffer from migraines might be able to predict when one is coming hours before symptoms even start.
May 6, 2024
The Washington Post highlighted research led by University of Cincinnati and Cincinnati Children's Hospital researchers that found kids eat fewer healthy foods and take in 22 percent of their day’s added sugar intake in the single hour after they’re picked up from child care.
March 22, 2024
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
February 29, 2024
Regional media highlighted the University of Cincinnati Cancer Center being the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.